Jefferies London 2026: Intellia is currently in front of FDA for the potential approval of the first in vivo (in the body) CRISPR gene editing therapy - it is for hereditary angioedema

0:00-9:34

President & CEO John Leonard discusses the program and compares and contrasts it to more traditional medicines. He also provides an update on the company's transthyretin (ATTR) amyloidosis with cardiomyopathy (ATTR-CM) program.

B-

BiotechTV - News

@biotechtvnews

#potentialapproval #crisprgeneediting #hereditaryangioedema #lifesciences

The Nile